Blueprint Medicines Corp (NAS:BPMC)
$ 102.71 -0.92 (-0.89%) Market Cap: 6.43 Bil Enterprise Value: 6.17 Bil PE Ratio: 0 PB Ratio: 20.71 GF Score: 74/100

Blueprint Medicines Corp To Discuss The FDA Approval of AYVAKIT in ISM Call Transcript

May 22, 2023 / 08:30PM GMT
Release Date Price: $56.25 (+2.76%)
Operator

Good afternoon, and thank you for attending today's Blueprint Medicines Conference Call. My name is Daniel, and I will be the moderator for today's call. (Operator Instructions) It is now my pleasure to pass the conference over to our host, Jenna Cohen with Blueprint. Jenna, the floor is yours.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Daniel, and good afternoon, everyone. It is an honor and a pleasure to welcome you to Blueprint Medicines conference call to discuss the U.S. FDA approval of AYVAKIT for indolent systemic mastocytosis. This afternoon, we issued a press release outlining this historic milestone for Blueprint Medicines and the SM community. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining us today are Kate Haviland, Chief Executive Officer; Becker Hewes, Chief Medical Officer; and Philina Lee,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot